greeksoup/ stock research
Stock research / United States / NVCR / Insiders

NovoCure Ltd. insider trading

In twelve months insiders at NovoCure bought nothing and sold $3.3M on the open market; none of the 25 sales was under a plan set in advance.

Bought on the open marketNonein twelve months
Sold on the open market$3.3M25 sales
Sales set in advanceNoneall 25 chosen by the insider
Pay taken in stockNone
New to this? How to read this page
  1. Insiders are the people who run the company: officers, directors and owners of 10% or more. They must report a trade on Form 4 within two business days.
  2. A purchase on the open market is the strongest sign: the insider spent their own money.
  3. A sale under a trading plan (Rule 10b5-1) says little: its dates were fixed months before. Sales outside a plan say more, but insiders sell for many reasons, such as taxes or a house.
  4. Grants, option exercises and shares held back for tax are left out.
  5. What is a Form 4? · Form 4 codes

What kind of trades

Insiders only sold: 25 sales worth $3.3M, each on a day the insider chose.

Purchasebought with their own money
Pay in stock, own choiceowed cash, chose shares
Sale outside a planthe insider picked the day
Sale under a plandates fixed months before
Says littlecompany plans, board pay, cash units
Bought
none
Sold
25 outside a plan

Every Form 4 line of the last twelve months, counted by kind. The grades come from the filing itself: whether the insider paid cash, whether a plan set the date, whether pay was taken in stock by choice.

Insider trades on the share price

last twelve months

24 marks over twelve months, each in its grade: solid for the stronger signs, hollow or grey for the ones that say little.

PurchasePay in stock, own choiceSale outside a planSale under a planSays little

The blue line is the daily close over twelve months. Each mark is one insider's trades on one day, on that day's price, sized by dollar value. Solid marks are the stronger signs; hollow and grey marks say little. Hover or tap a mark for who, how much and why.

Trades worth a closer look

A purchase stands out when two or more of these hold: a senior insider, several insiders buying within 90 days, a fall of 10% or more in the three months before, or over $1 million. A sale outside a plan is judged the same way. These are the Feed's rules.

Who traded

dollars, twelve months

12 insiders traded. The most: Doyle William F, sale outside a plan $933K.

One row per insider, sold to the left and bought to the right, split by grade: the paler part of a bar is the part that says little.

How it compares

every company on the site

Open-market sales, twelve months

Open-market purchases, twelve months

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every Form 4 line

    Purchase: bought on the open market with their own moneyTook pay in stock, own choice: owed cash, chose shares instead; a softer signSale: sold on the open market, not under a plan set in advanceSale, trading plan: under a Rule 10b5-1 plan set up months before, so the date was fixed in advanceGrey lines: plan purchases, pay in stock taken by the whole board or under a company plan, and units paid in cash; they say little about the insider's own view
    TradedInsiderRoleTypeSharesPriceValueFiling
    4 June 2026Leonard Frank XChief Executive OfficerSaleafter a 26% rise over three months · 3% below its one-year high · Form 144 notice 4 June 202634,273$17.93$614,635Form 4
    2 June 2026Leung GabrielDirectorSaleafter a 19% rise over three months · 14% below its one-year high2,945$15.77$46,445Form 4
    2 June 2026Stafford KristinDirectorSaleafter a 19% rise over three months · 14% below its one-year high2,945$15.77$46,445Form 4
    2 June 2026Ocean Allyson JDirectorSaleafter a 19% rise over three months · 14% below its one-year high2,945$15.77$46,445Form 4
    2 June 2026Scannell Timothy JDirectorSaleafter a 19% rise over three months · 14% below its one-year high2,945$15.77$46,445Form 4
    2 June 2026Hilleman Jeryl LDirectorSaleafter a 19% rise over three months · 14% below its one-year high2,945$15.77$46,445Form 4
    2 June 2026Vernon W AnthonyDirectorSaleafter a 19% rise over three months · 14% below its one-year high2,945$15.77$46,445Form 4
    2 June 2026Hung DavidDirectorSaleafter a 19% rise over three months · 14% below its one-year high2,945$15.77$46,445Form 4
    5 March 2026Paravasthu MukundChief Operating OfficerSaleafter a 21% rise over three months · 33% below its one-year high · Form 144 notice 5 March 202643,246$13.77$595,670Form 4
    4 March 2026Leupin NicolasFormer Chief Medical OfficerSaleafter a 14% rise over three months · 37% below its one-year high1,100$13.31$14,636Form 4
    4 March 2026Weinberg UriChf Medical and Innovation OfrSaleafter a 14% rise over three months · 37% below its one-year high · Form 144 notice 4 March 20266,412$13.31$85,314Form 4
    4 March 2026Brackmann ChristophChief Financial OfficerSaleafter a 14% rise over three months · 37% below its one-year high · Form 144 notice 4 March 20266,412$13.31$85,314Form 4
    4 March 2026Leonard Frank XChief Executive OfficerSaleafter a 14% rise over three months · 37% below its one-year high · Form 144 notice 4 March 20265,607$13.31$74,603Form 4
    4 March 2026Paravasthu MukundChief Operating OfficerSaleafter a 14% rise over three months · 37% below its one-year high · Form 144 notice 5 March 20265,377$13.31$71,543Form 4
    4 March 2026Puri Michal NathChief Human Resources OfficerSaleafter a 14% rise over three months · 37% below its one-year high1,100$13.31$14,636Form 4
    3 March 2026Doyle William FExecutive ChairmanSaleafter a 22% rise over three months · 38% below its one-year high · Form 144 notice 3 March 202650,557$12.79$646,447Form 4
    3 March 2026Doyle William FExecutive ChairmanSaleafter a 22% rise over three months · 38% below its one-year high · Form 144 notice 3 March 202621,330$13.43$286,436Form 4
    2 March 2026Weinberg UriChf Medical and Innovation OfrSaleafter a 16% rise over three months · 37% below its one-year high · Form 144 notice 2 March 20263,272$13.33$43,607Form 4
    2 March 2026Paravasthu MukundChief Operating OfficerSaleafter a 16% rise over three months · 37% below its one-year high408$13.49$5,505Form 4
    2 March 2026Leonard Frank XChief Executive OfficerSaleafter a 16% rise over three months · 37% below its one-year high · Form 144 notice 2 March 20267,232$13.49$97,581Form 4
    27 February 2026Weinberg UriChf Medical and Innovation OfrSaleafter a 7% rise over three months · 36% below its one-year high · Form 144 notice 27 February 20267,461$13.84$103,257Form 4
    27 February 2026Puri Michal NathChief Human Resources OfficerSaleafter a 7% rise over three months · 36% below its one-year high1,441$13.66$19,690Form 4
    27 February 2026Paravasthu MukundChief Operating OfficerSaleafter a 7% rise over three months · 36% below its one-year high1,555$13.66$21,247Form 4
    27 February 2026Leupin NicolasFormer Chief Medical OfficerSaleafter a 7% rise over three months · 36% below its one-year high1,029$13.66$14,060Form 4
    27 February 2026Leonard Frank XChief Executive OfficerSaleafter a 7% rise over three months · 36% below its one-year high · Form 144 notice 27 February 20269,734$13.66$133,003Form 4
    A filing with several lines appears once per line.
    Read morePay taken in stock by the insider's own choice has the filing's footnote, word for word, in the note under it; for the others, hold the pointer on the type. An award filed at no price shows n/a.